{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:14:30Z","timestamp":1785777270844,"version":"3.56.0"},"reference-count":51,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T00:00:00Z","timestamp":1419897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Rapamycin\u2010related mTOR inhibitors (rapalogs) possess immunosuppressive and antiproliferative properties. Their mechanism of action makes them attractive therapies for several disease states but also potentiates adverse effects associated with these drugs. The oral mTOR inhibitor everolimus was recently approved for the treatment of tuberous sclerosis complex (TSC)\u2010associated renal angiomyolipoma. As clinical use of rapalogs for the treatment of TSC increases, nephrologists and urologists who treat both children and adults with renal masses, as well as internists and geneticists with an interest in renal disease, should be aware of their safety profiles. This review presents the clinical experience of rapamycin\u2010related mTOR inhibitors in patients with TSC and summarizes their toxicity profiles in renal transplant and TSC populations. Increased usage of rapalogs in a variety of patient populations demands vigilant monitoring of their safety profiles and rigorous differentiation between disease\u2010specific and drug\u2010specific toxicities.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcph.428","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T09:17:31Z","timestamp":1416215851000},"page":"368-376","source":"Crossref","is-referenced-by-count":23,"title":["Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation"],"prefix":"10.1002","volume":"55","author":[{"given":"Michael J.G.","family":"Somers","sequence":"first","affiliation":[{"name":"Division of Nephrology Boston Children's Hospital Boston MA USA"},{"name":"Department of Pediatrics Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahna","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Harvard Medical School Boston MA USA"},{"name":"Herscot Center for TSC and Division of Pediatric Nephrology Massachusetts General Hospital Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2012.09.008"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2011.558079"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.28.727"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.06.087"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0166"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25219"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443020-00002"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.93"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.28"},{"key":"e_1_2_7_12_1","unstructured":"Rapamuner (sirolimus) oral solution and tablets [package insert]. Philadelphia. PA: Pfizer; July2011."},{"key":"e_1_2_7_13_1","unstructured":"Zortress (tablets for oral administration) [package insert]. Stein. Switzerland: Novartis Pharma Stein AG; March2013."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61279-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.06.009"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063564"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0445"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023379"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001671"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-87"},{"key":"e_1_2_7_23_1","unstructured":"Afinitor (everolimus tablets for oral administration); Afinitor Disperz (everolimus tablets for oral suspension) [package insert]. East Hanover. NJ: Novartis Pharmaceuticals Corporation; February2014."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr511"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200911-1720OC"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.662955"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02272.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.02.014"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-9912"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"issue":"1","key":"e_1_2_7_31_1","first-page":"S11","article-title":"Standards of medical care in diabetes: 2011","volume":"34","year":"2012","journal-title":"Diabetes Care"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2011.01357.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2011.01575.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318211d342"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.01.045"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200212150-00013"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318187bab0"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000177644.45192.a3"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:DDAS.0000034567.53748.df"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2011.601826"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318193886e"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1113145"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-009-9644-8"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6135.2003.00279.x"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2006.00423.x"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02267.x"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20784"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1399-3046.2003.00137.x"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2007.00832.x"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03266.x"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2459-y"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.428","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T14:08:46Z","timestamp":1696342126000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,30]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/jcph.428"],"URL":"https:\/\/doi.org\/10.1002\/jcph.428","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,30]]}}}